About Deep Genomics
Deep Genomics is a company based in Toronto (Canada) founded in 2015. Deep Genomics has raised $237.96 million across 4 funding rounds from investors including Fidelity Investments, ARE and Khosla Ventures. Deep Genomics offers products and services including AI Platform, BigRNA, and BigRNA+. Deep Genomics operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
- Headquarter Toronto, Canada
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$237.96 M (USD)
in 4 rounds
-
Latest Funding Round
$180 M (USD), Series C
Jul 28, 2021
-
Investors
Fidelity Investments
& 12 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Deep Genomics
Deep Genomics offers a comprehensive portfolio of products and services, including AI Platform, BigRNA, and BigRNA+.
Uses AI to identify RNA targets and evaluate therapies for genetic conditions.
Foundation model for analyzing RNA biology and discovering new mechanisms.
Expanded model for pursuing complex genetic diseases and novel targets.
People of Deep Genomics
Unlock access to complete
Unlock access to complete
Funding Insights of Deep Genomics
Deep Genomics has successfully raised a total of $237.96M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $180 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Deep Genomics
Deep Genomics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, ARE and Khosla Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology and startups.
|
Locked | Locked | Locked | |
|
Venture capital investments are made in precision medicine companies.
|
Locked | Locked | Locked | |
|
Early-stage startups are funded by this venture capital firm.
|
Locked | Locked | Locked |
Investor details for Deep Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Deep Genomics
Investment portfolio details for Deep Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Deep Genomics
Detailed financials for Deep Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Deep Genomics Comparisons
Peer comparison for Deep Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Deep Genomics
Deep Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
Detailed competitors of Deep Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Deep Genomics
Complete news archive for Deep Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Deep Genomics
Deep Genomics was founded in 2015.
Deep Genomics is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Deep Genomics is a funded company, having raised a total of $237.96M across 4 funding rounds to date.
Deep Genomics has expertise in machine learning, genome biology and precision medicine. They are working on a new generation of computational technologies that can tell what will happen within a cell when DNA is altered by genetic variation, whether natural or therapeutic using machine learning and deep learning techniques. Their first product is SPIDEX, a comprehensive set of mutations and their predicted effects on RNA splicing across the entire human genome. They are making the SPIDEX database free for non-commercial purposes.
Deep Genomics's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
Deep Genomics offers AI Platform, BigRNA, and BigRNA+.
Deep Genomics has 13 investors. Key investors include Fidelity Investments, ARE, Khosla Ventures, CPP Investments, and Kensington Capital Partners.